NewsRelease
Journal Article Cites AlbuSorb™for Analysis of High-fat Diet–induced Metabolic Changes
MONMOUTHJUNCTION, NJ,March19, 2021 -- Biotech Support Group reports on a recent journal articleusing AlbuSorb™to determine the amount of circulating apoCIII in plasma, a keyregulator of lipid metabolism.
Thecitation is:
Valladolid-Acebes,Ismael, et al. "Loweringapolipoprotein CIII protects against high-fat diet–inducedmetabolic derangements." ScienceAdvances 7.11(2021): eabc2931.
Increasedlevels of apolipoprotein CIII (apoCIII), result in obesity-relatedmetabolic derangements. Using mice, the researchers investigatedmechanistically whether lowering or preventing high-fat diet (HFD)–induced increase in apoCIII, protects against the detrimentalmetabolic consequences. For Western blotting determination ofcirculating apoCIII, the article states, “plasma was albumindepleted using AlbuSorb according to the manufacturer’s protocol(Biotech Support Group LLC) and resuspended in 0.1% (v/v)trifluoroacetic acid.” The research concludes that lowering apoCIIIprotects against and reverses the HFD-induced metabolic phenotype bypromoting physiological insulin sensitivity.
“Thisreference shows that AlbuSorb™ is very selective fordepleting albumin and enriching the apolipoprotein fraction includingapoCIII. Without the associated interference fromAlbumin, Western blot analysis becomes muchmore defined. Also, as our bead technology does not rely onimmuno-affinity, it works for all species; mice in this example.”,states Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup.
Formore information visit: AlbuSorb™at
http://www.biotechsupportgroup.com/AlbuSorb-Albumin-Depletion-Kit-p/a185.htm
Formore information on our complete line of Albumin & IgG Removal,visit:
https://www.biotechsupportgroup.com/Albumin-Removal-s/307.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, gotohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc
732-274-2866